REGN- Regeneron Pharmaceuticals, Inc.
Healthcare · Biotechnology
Price & Performance
Performance
Analysis & Verdict
Analyst Ratings
BuyWall Street consensus from 27 analysts
12-Month Price Target
$849.32
Based on analyst estimates; price targets are opinions, not guarantees.
Fair Value Estimates
Current price: $781.49
Graham Number
√(22.5 × EPS × Book Value)
$536.05
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$58.67
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
7/10
70% score
Pays dividends
1Y hist.1+ years of dividend history
Dividend consistency (5Y+)
1 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
14.0%Return on equity - measures how efficiently capital is used
Positive profit margin
27.9%Net profit margin must be positive - company earns more than it spends
Revenue growth (annual)
+16.7%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
-4.5%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
8.54×Low financial leverage reduces risk of distress
Current ratio above 1
3.33×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$637M/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
0.48%Stock must distribute income to shareholders
Financials
Revenue & Results
Key Statistics
Earnings
Next Earnings
Oct 28, 2026
46
days
EPS (TTM)
$40.40
P/E (TTM)
19.3
Fwd P/E
12.9
SEC Filings & Reported Financials
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Insider Transactions
SEC Form 4 · officers, directors & 10% owners
Dividends & Income
Dividends
Current DY
0.48%
5Y Avg Annual
$1.2680
Last Payment
$0.9400
Ex-Date
08/18/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest08/18/2026 | 08/31/2026 | $0.9400 | 0.48% |
05/20/2026 | 06/02/2026 | $0.9400 | 0.48% |
02/20/2026 | 03/05/2026 | $0.9400 | 0.48% |
11/20/2025 | 12/03/2025 | $0.8800 | 0.45% |
08/18/2025 | 08/31/2025 | $0.8800 | 0.45% |
05/20/2025 | 06/02/2025 | $0.8800 | 0.45% |
02/20/2025 | 03/05/2025 | $0.8800 | 0.45% |
Magic Number
Shares needed to self-fund your next purchase
$781.49
Price
$0.9400
Last div. (quarterly)
832
shares
Own 832 REGN shares ($650,199.68) and each quarterly dividend pays for 1 new share - the snowball runs on its own.
Investment target
$650,199.68
New shares / year
+4 shares
Dividend Calculator
0.48% yieldEstimate REGN dividend income at the current rate.
Per year
$48.11
Per month
$4.01
≈ 12.8 shares at $3.76/share a year. Estimate only - dividends can be cut or raised.
Tools & Simulators
REGN vs Peers, Indexes & Commodities
?Click a card below to plot it on the chart
Loading history…
Parameters
Final value
$426,404.61
Total invested
$130,000.00
Total interest
$296,404.61
Balance over time
Period breakdown
| Period | Balance | Invested | Interest |
|---|---|---|---|
| Start | $10,000.00 | $10,000.00 | $0.00 |
| Year 1 | $17,270.27 | $16,000.00 | $1,270.27 |
| Year 2 | $25,267.56 | $22,000.00 | $3,267.56 |
| Year 3 | $34,064.59 | $28,000.00 | $6,064.59 |
| Year 4 | $43,741.32 | $34,000.00 | $9,741.32 |
| Year 5 | $54,385.72 | $40,000.00 | $14,385.72 |
| Year 6 | $66,094.55 | $46,000.00 | $20,094.55 |
| Year 7 | $78,974.28 | $52,000.00 | $26,974.28 |
| Year 8 | $93,141.97 | $58,000.00 | $35,141.97 |
| Year 9 | $108,726.44 | $64,000.00 | $44,726.44 |
| Year 10 | $125,869.35 | $70,000.00 | $55,869.35 |
| Year 11 | $144,726.56 | $76,000.00 | $68,726.56 |
| Year 12 | $165,469.48 | $82,000.00 | $83,469.48 |
| Year 13 | $188,286.70 | $88,000.00 | $100,286.70 |
| Year 14 | $213,385.63 | $94,000.00 | $119,385.63 |
| Year 15 | $240,994.47 | $100,000.00 | $140,994.47 |
| Year 16 | $271,364.18 | $106,000.00 | $165,364.18 |
| Year 17 | $304,770.87 | $112,000.00 | $192,770.87 |
| Year 18 | $341,518.22 | $118,000.00 | $223,518.22 |
| Year 19 | $381,940.31 | $124,000.00 | $257,940.31 |
| Year 20 | $426,404.61 | $130,000.00 | $296,404.61 |
What is compound interest?
Compound interest means that the interest you earn in one period is added to your principal, so in the next period you earn interest on a larger base. This creates exponential growth: the longer your time horizon, the more dramatic the effect.
Which rate should I use?
The S&P 500 has historically returned ~10%/year before inflation over long periods - use this for an all-equity US index fund scenario. A balanced growth portfolio (stocks + bonds) is closer to 7%. High-yield savings accounts (HYSA) are currently paying around 4-5% with FDIC insurance and zero market risk. Bonds historically return ~4% annualized.
Formula used
FV = PV × (1+r)^n + PMT × ((1+r)^n − 1) / rwhere r is the monthly rate, n is the number of months, PV is the initial investment, and PMT is the monthly contribution. Annual rates are converted to monthly viar = (1 + annual%)^(1/12) − 1.
For educational purposes only. Not financial advice. Past returns do not guarantee future results.
Discussion
Sign in to join the discussionSign inLoading…
Discover
Related Assets
Healthcare
Related Articles
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Sector
Healthcare
Industry
Biotechnology
Location
Tarrytown, United States
Employees
15,410
Stock Market ROI Pro
All features, zero ads- web & app
Unlock every feature, ad-free, across our website and iOS app.
Regeneron Pharmaceuticals, Inc. (REGN) stock trades at $781.49, down 1.48% on the day. With a market capitalization of $80.46 billion, REGN is a large-cap healthcare stock. It trades at a price-to-earnings (P/E) ratio of 19.3, a forward P/E of 12.9 and earnings per share (EPS) of $40.40. Over the most recent period the company reported 17% year-over-year revenue growth and a net profit margin of 27.9%. Below you'll find REGN's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.
REGN - Frequently Asked Questions
Is Regeneron Pharmaceuticals, Inc. (REGN) a good stock to buy in 2026?
Regeneron Pharmaceuticals, Inc. (REGN) shows strengths such as revenue growth of 17% and a strong 28% net margin, while risks include high leverage (debt/equity of 8.5). Whether REGN is a good buy in 2026 depends on your time horizon and risk tolerance - review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.
What is REGN's stock price today?
Regeneron Pharmaceuticals, Inc. (REGN) trades at $781.49, down 1.48% on the session. Prices on this page update throughout the trading day.
Does REGN pay a dividend?
Yes. Regeneron Pharmaceuticals, Inc. pays an annual dividend of $3.76 per share, a dividend yield of 0.48%. The most recent ex-dividend date was August 18, 2026. Its payout ratio is about 9% of earnings.
Is REGN overvalued?
With a P/E ratio of 19.3×, REGN trades at a roughly market-average valuation for the healthcare sector. Its PEG ratio is 1.14. See the Fair Value Estimates section above for Graham Number and dividend-based price targets.
What is REGN's market cap?
Regeneron Pharmaceuticals, Inc. (REGN) has a market capitalization of $80.46 billion, classifying it as a large-cap stock in the Healthcare sector.
Disclaimer: This page - including any buy/hold/avoid view, fair value or price estimate - is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.